All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Cerebrospinal Fluid Levels of Chromogranin A in Parkinson's Disease and Multiple System Atrophy

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F21%3AA22029PK" target="_blank" >RIV/61988987:17110/21:A22029PK - isvavai.cz</a>

  • Alternative codes found

    RIV/61989592:15110/21:73609588 RIV/00843989:_____/21:E0108820 RIV/00098892:_____/21:N0000083

  • Result on the web

    <a href="https://www.mdpi.com/2076-3425/11/2/141" target="_blank" >https://www.mdpi.com/2076-3425/11/2/141</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.3390/brainsci11020141" target="_blank" >10.3390/brainsci11020141</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Cerebrospinal Fluid Levels of Chromogranin A in Parkinson's Disease and Multiple System Atrophy

  • Original language description

    Background: Chromogranin A (CgA) and other peptides from the chromogranin- secretogranin family have been recently studied as potential biomarkers of various neurodegenerative diseases, including Parkinson's disease (PD). Methods: We measured CgA in the cerebrospinal fluid (CSF) of 119 PD patients, 18 multiple system atrophy (MSA) patients, and 31 age-matched controls. We also correlated the values with disease duration and levodopa dose equivalent. Results: In the PD patients, CSF CgA tended to be lower than the control group (median 124.5 vs. 185.2 mu g/L; p = 0.057); however, the results did not reach statistical significance. CSF CgA levels in MSA were significantly lower compared to the control group (median 104.4 vs. 185.2; p = 0.014). There was no significant difference in CSF CgA between PD and MSA patients (p = 0.372). There was no association between CSF CgA and disease duration or levodopa dose equivalent in PD or in MSA. Conclusions: We observed a tendency toward lower CSF CgA levels in both PD and MSA compared to the control group; however, the difference reached statistical significance only in MSA. Based on these results, CgA may have potential as a biomarker in PD and MSA, but further studies on larger numbers of patients are needed to draw conclusions.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30103 - Neurosciences (including psychophysiology)

Result continuities

  • Project

    <a href="/en/project/EF16_019%2F0000868" target="_blank" >EF16_019/0000868: Molecular, cellular and clinical approach to healthy ageing</a><br>

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2021

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Brain Sciences

  • ISSN

    2076-3425

  • e-ISSN

  • Volume of the periodical

    11

  • Issue of the periodical within the volume

    2

  • Country of publishing house

    CH - SWITZERLAND

  • Number of pages

    6

  • Pages from-to

  • UT code for WoS article

    000622243200001

  • EID of the result in the Scopus database